Does the media refer more to BBNX or ESTA?

In the previous week, Beta Bionics had 1 more articles in the media than Establishment Labs. MarketBeat recorded 3 mentions for Beta Bionics and 2 mentions for Establishment Labs. Beta Bionics' average media sentiment score of 1.08 beat Establishment Labs' score of 0.94 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BBNX or TMDX?

In the previous week, TransMedics Group had 1 more articles in the media than Beta Bionics. MarketBeat recorded 4 mentions for TransMedics Group and 3 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.08 beat TransMedics Group's score of 0.74 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBNX or LMAT?

In the previous week, LeMaitre Vascular had 1 more articles in the media than Beta Bionics. MarketBeat recorded 4 mentions for LeMaitre Vascular and 3 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.08 beat LeMaitre Vascular's score of 0.04 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, BBNX or AXGN?

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $100.25M 7.74 -$73.20M -$1.51 N/A AxoGen $238.11M 8.64 -$15.70M -$0.64 N/A

Is BBNX or AXGN more profitable?

AxoGen has a net margin of -13.21% compared to Beta Bionics' net margin of -60.27%. AxoGen's return on equity of -9.63% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -60.27% -23.00% -20.55% AxoGen -13.21% -9.63% -6.26%

Does the media refer more to BBNX or AXGN?

In the previous week, AxoGen had 3 more articles in the media than Beta Bionics. MarketBeat recorded 6 mentions for AxoGen and 3 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.08 beat AxoGen's score of 0.93 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BFLY or BBNX?

In the previous week, Butterfly Network had 6 more articles in the media than Beta Bionics. MarketBeat recorded 9 mentions for Butterfly Network and 3 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.08 beat Butterfly Network's score of -0.11 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 1 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Beta Bionics (BBNX) Competitors

$17.40 +0.55 (+3.23%)

As of 11:21 AM Eastern

Compare

BBNX vs. ESTA, TMDX, LMAT, AXGN, and BFLY

Should you buy Beta Bionics stock or one of its competitors? MarketBeat compares Beta Bionics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Beta Bionics include Establishment Labs (ESTA), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), AxoGen (AXGN), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry.

How does Beta Bionics compare to Establishment Labs?

Beta Bionics (NASDAQ:BBNX) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Establishment Labs has higher revenue and earnings than Beta Bionics. Establishment Labs is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	7.74	-$73.20M	-$1.51	N/A
Establishment Labs	$211.08M	12.52	-$51.06M	-$1.49	N/A

Establishment Labs has a net margin of -19.05% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Establishment Labs	-19.05%	-218.77%	-12.31%

Beta Bionics has a beta of 3.04, suggesting that its share price is 204% more volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

In the previous week, Beta Bionics had 1 more articles in the media than Establishment Labs. MarketBeat recorded 3 mentions for Beta Bionics and 2 mentions for Establishment Labs. Beta Bionics' average media sentiment score of 1.08 beat Establishment Labs' score of 0.94 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beta Bionics currently has a consensus price target of $20.30, indicating a potential upside of 16.63%. Establishment Labs has a consensus price target of $90.43, indicating a potential upside of 0.72%. Given Beta Bionics' higher probable upside, equities analysts clearly believe Beta Bionics is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

72.9% of Establishment Labs shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 10.0% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Establishment Labs beats Beta Bionics on 10 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to TransMedics Group?

Beta Bionics (NASDAQ:BBNX) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

TransMedics Group has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	7.74	-$73.20M	-$1.51	N/A
TransMedics Group	$605.49M	4.35	$190.29M	$4.40	17.30

Beta Bionics has a beta of 3.04, indicating that its stock price is 204% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

Beta Bionics presently has a consensus price target of $20.30, indicating a potential upside of 16.63%. TransMedics Group has a consensus price target of $134.50, indicating a potential upside of 76.66%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

99.7% of TransMedics Group shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TransMedics Group has a net margin of 27.04% compared to Beta Bionics' net margin of -60.27%. TransMedics Group's return on equity of 22.38% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
TransMedics Group	27.04%	22.38%	8.46%

In the previous week, TransMedics Group had 1 more articles in the media than Beta Bionics. MarketBeat recorded 4 mentions for TransMedics Group and 3 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.08 beat TransMedics Group's score of 0.74 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TransMedics Group beats Beta Bionics on 11 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to LeMaitre Vascular?

Beta Bionics (NASDAQ:BBNX) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

84.6% of LeMaitre Vascular shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

LeMaitre Vascular has a net margin of 24.35% compared to Beta Bionics' net margin of -60.27%. LeMaitre Vascular's return on equity of 15.36% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
LeMaitre Vascular	24.35%	15.36%	9.78%

In the previous week, LeMaitre Vascular had 1 more articles in the media than Beta Bionics. MarketBeat recorded 4 mentions for LeMaitre Vascular and 3 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.08 beat LeMaitre Vascular's score of 0.04 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beta Bionics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Beta Bionics presently has a consensus price target of $20.30, suggesting a potential upside of 16.63%. LeMaitre Vascular has a consensus price target of $112.60, suggesting a potential upside of 12.99%. Given Beta Bionics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Beta Bionics is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

LeMaitre Vascular has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	7.74	-$73.20M	-$1.51	N/A
LeMaitre Vascular	$249.60M	9.12	$57.73M	$2.71	36.77

Summary

LeMaitre Vascular beats Beta Bionics on 11 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to AxoGen?

Beta Bionics (NASDAQ:BBNX) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Beta Bionics has a beta of 3.04, meaning that its stock price is 204% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Beta Bionics presently has a consensus target price of $20.30, indicating a potential upside of 16.63%. AxoGen has a consensus target price of $46.50, indicating a potential upside of 20.20%. Given AxoGen's stronger consensus rating and higher probable upside, analysts clearly believe AxoGen is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

80.3% of AxoGen shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, AxoGen had 3 more articles in the media than Beta Bionics. MarketBeat recorded 6 mentions for AxoGen and 3 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.08 beat AxoGen's score of 0.93 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen has a net margin of -13.21% compared to Beta Bionics' net margin of -60.27%. AxoGen's return on equity of -9.63% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
AxoGen	-13.21%	-9.63%	-6.26%

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	7.74	-$73.20M	-$1.51	N/A
AxoGen	$238.11M	8.64	-$15.70M	-$0.64	N/A

Summary

AxoGen beats Beta Bionics on 12 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, Butterfly Network had 6 more articles in the media than Beta Bionics. MarketBeat recorded 9 mentions for Butterfly Network and 3 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.08 beat Butterfly Network's score of -0.11 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	1 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beta Bionics has a net margin of -60.27% compared to Butterfly Network's net margin of -73.63%. Beta Bionics' return on equity of -23.00% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
Beta Bionics	-60.27%	-23.00%	-20.55%

Butterfly Network has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the broader market.

Butterfly Network presently has a consensus price target of $5.56, indicating a potential downside of 25.49%. Beta Bionics has a consensus price target of $20.30, indicating a potential upside of 16.63%. Given Beta Bionics' stronger consensus rating and higher probable upside, analysts plainly believe Beta Bionics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

37.9% of Butterfly Network shares are held by institutional investors. 22.0% of Butterfly Network shares are held by insiders. Comparatively, 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Beta Bionics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	19.47	-$77.06M	-$0.30	N/A
Beta Bionics	$100.25M	7.74	-$73.20M	-$1.51	N/A

Summary

Beta Bionics beats Butterfly Network on 12 of the 17 factors compared between the two stocks.

Get Beta Bionics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBNX vs. The Competition

Export

Metric	Beta Bionics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$775.57M	$7.44B	$6.78B	$12.59B
Dividend Yield	N/A	1.31%	2.68%	8.42%
P/E Ratio	-11.53	50.26	26.98	24.43
Price / Sales	7.74	45.78	519.22	91.44
Price / Cash	N/A	26.31	48.59	59.36
Price / Book	2.67	7.20	10.92	6.33
Net Income	-$73.20M	$162.30M	$3.59B	$331.13M
7 Day Performance	7.57%	0.93%	-1.32%	0.39%
1 Month Performance	21.04%	-0.17%	2.92%	-0.53%
1 Year Performance	38.91%	7.86%	28.48%	20.45%

Beta Bionics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBNX Beta Bionics	2.4017 of 5 stars	$17.41 +3.2%	$20.30 +16.6%	+31.4%	$775.57M	$100.25M	N/A	294	Positive News Analyst Forecast
ESTA Establishment Labs	1.3113 of 5 stars	$88.03 -0.8%	$89.71 +1.9%	+90.2%	$2.59B	$211.08M	N/A	1,004	Analyst Forecast
TMDX TransMedics Group	4.3575 of 5 stars	$71.23 -1.3%	$134.50 +88.8%	-36.2%	$2.46B	$605.49M	16.19	210
LMAT LeMaitre Vascular	3.9466 of 5 stars	$102.74 +0.3%	$112.60 +9.6%	+16.4%	$2.35B	$256.28M	37.91	490	News Coverage
AXGN AxoGen	3.0904 of 5 stars	$40.58 -7.0%	$46.50 +14.6%	+222.5%	$2.16B	$225.21M	N/A	450	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBNX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beta Bionics (BBNX) Competitors

BBNX vs. ESTA, TMDX, LMAT, AXGN, and BFLY

How does Beta Bionics compare to Establishment Labs?

Summary

How does Beta Bionics compare to TransMedics Group?

Summary

How does Beta Bionics compare to LeMaitre Vascular?

Summary

How does Beta Bionics compare to AxoGen?

Summary

How does Beta Bionics compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beta Bionics (BBNX) Competitors

BBNX vs. ESTA, TMDX, LMAT, AXGN, and BFLY

How does Beta Bionics compare to Establishment Labs?

Which has preferable earnings & valuation, BBNX or ESTA?

Is BBNX or ESTA more profitable?

Which has more risk and volatility, BBNX or ESTA?

Does the media refer more to BBNX or ESTA?

Do analysts recommend BBNX or ESTA?

Do institutionals and insiders have more ownership in BBNX or ESTA?

Summary

How does Beta Bionics compare to TransMedics Group?

Which has preferable valuation and earnings, BBNX or TMDX?

Which has more volatility and risk, BBNX or TMDX?

Do analysts rate BBNX or TMDX?

Do institutionals and insiders have more ownership in BBNX or TMDX?

Is BBNX or TMDX more profitable?

Does the media refer more to BBNX or TMDX?

Summary

How does Beta Bionics compare to LeMaitre Vascular?

Do insiders and institutionals hold more shares of BBNX or LMAT?

Is BBNX or LMAT more profitable?

Does the media prefer BBNX or LMAT?

Which has more risk and volatility, BBNX or LMAT?

Do analysts rate BBNX or LMAT?

Which has higher valuation and earnings, BBNX or LMAT?

Summary

How does Beta Bionics compare to AxoGen?

Which has more risk and volatility, BBNX or AXGN?

Do analysts recommend BBNX or AXGN?

Do institutionals and insiders believe in BBNX or AXGN?

Does the media refer more to BBNX or AXGN?

Is BBNX or AXGN more profitable?

Which has preferable earnings & valuation, BBNX or AXGN?

Summary

How does Beta Bionics compare to Butterfly Network?

Does the media prefer BFLY or BBNX?

Is BFLY or BBNX more profitable?

Which has more volatility & risk, BFLY or BBNX?

Do analysts rate BFLY or BBNX?

Do insiders and institutionals believe in BFLY or BBNX?

Which has better earnings & valuation, BFLY or BBNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools